{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 1408"}, "official-title": {"#tail": "\n\t", "#text": "To amend the Federal Food, Drug, and Cosmetic Act to\n\t\t  reauthorize user fee programs relating to generic new animal\n\t\t  drugs."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130409", "#text": "April 9, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and\n\t\t\t Commerce"}, "sponsor": {"#tail": " (for\n\t\t\t himself, ", "#text": "Mr. Gardner", "@name-id": "G000562"}, "cosponsor": [{"#tail": ",\n\t\t\t ", "#text": "Mr. Shimkus", "@name-id": "S000364"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Upton", "@name-id": "U000031"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Pitts", "@name-id": "P000373"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Waxman", "@name-id": "W000215"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Pallone", "@name-id": "P000034"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Burgess", "@name-id": "B001248"}, {"#tail": ", and\n\t\t\t ", "#text": "Mr. Guthrie", "@name-id": "G000558"}, {"#tail": ") introduced\n\t\t\t the following bill; which was referred to the\n\t\t\t ", "#text": "Mr. Kinzinger of Illinois", "@name-id": "K000378"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H98E4A13470E949D9971AF5DEB9240AB5", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n\t\t\t", "#text": "Short title; finding"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "quote": {"#tail": ".", "#text": "Animal Generic Drug\n\t\t\t User Fee Amendments of 2013"}, "#text": "This Act may be cited as the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Short\n\t\t\t title"}, "#text": "\n        ", "@id": "H528A135473654C74949FEC8708B324EF"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "The\n\t\t\t fees authorized by this Act will be dedicated toward expediting the generic new\n\t\t\t animal drug development process and the review of abbreviated applications for\n\t\t\t generic new animal drugs, supplemental abbreviated applications for generic new\n\t\t\t animal drugs, and investigational submissions for generic new animal drugs as\n\t\t\t set forth in the goals identified in the letters from the Secretary of Health\n\t\t\t and Human Services to the Chairman of the Committee on Energy and Commerce of\n\t\t\t the House of Representatives and the Chairman of the Committee on Health,\n\t\t\t Education, Labor, and Pensions of the Senate as set forth in the Congressional\n\t\t\t Record."}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Finding"}, "#text": "\n        ", "@id": "HFAAB7FA7BA004118A73254E6E6012413", "@commented": "no"}], "#text": "\n      ", "@id": "H470F7EA38A82491393D835FC02435CA9"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 741 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:741"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/379j-21", "#text": "21 U.S.C. 379j\u201321", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Authority to\n\t\t\t assess and use generic new animal drug fees"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "741."}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Authority to\n\t\t\t\tassess and use generic new animal drug fees"}, "subsection": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tshall assess and collect fees in accordance with this section as\n\t\t\t\tfollows:", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Beginning with respect to fiscal year 2009, the "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "Types of\n\t\t\t\tfees"}, "paragraph": [{"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for such an application.", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, "#text": "Each person that submits, on or after July 1, 2008, an\n\t\t\t\tabbreviated application for a generic new animal drug shall be subject to a fee\n\t\t\t\tas established in "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                ", "@id": "HE4D7CD2C01AF431F860E39B7E20148D8"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be due upon submission of the\n\t\t\t\tabbreviated application.", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:A", "@proposed": "true"}, "#text": "The\n\t\t\t\tfee required by "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Payment"}, "#text": "\n                ", "@id": "H4BFB323FEB904C3A8918C06030416DFB"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:A", "@proposed": "true"}, "#text": "If an abbreviated application was submitted by a\n\t\t\t\tperson that paid the fee for such application, was accepted for filing, and was\n\t\t\t\tnot approved or was withdrawn (without a waiver or refund), the submission of\n\t\t\t\tan abbreviated application for the same product by the same person (or the\n\t\t\t\tperson\u2019s licensee, assignee, or successor) shall not be subject to a fee under\n\t\t\t\t"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "header": {"#tail": "\n                  ", "#text": "Previously filed\n\t\t\t\tapplication"}, "#text": "\n                  ", "@id": "H1FB4ABDDB01F4931AB0900533F5ADEDC"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and\n\t\t\t\tsubmitted on or after October 1, 2013, shall be subject to a fee equal to 50\n\t\t\t\tpercent of the amount of the abbreviated application fee established in\n\t\t\t\t", "@entity-type": "act", "#text": "section 512(d)(4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}], "#text": "An\n\t\t\t\tabbreviated application for an animal drug described in "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "header": {"#tail": "\n                  ", "#text": "Certain\n\t\t\t\tabbreviated applications involving combination animal drugs"}, "#text": "\n                  ", "@id": "HCABAA7A60E0E4A7EB550305208C22318"}], "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Exceptions"}, "#text": "\n                ", "@id": "HBA641E2B7DB348DF88E0CBA5AA3695AE"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall refund 75\n\t\t\t\tpercent of the fee paid under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " for any abbreviated application\n\t\t\t\twhich is refused for filing.", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:B", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "header": {"#tail": "\n                ", "#text": "Refund of fee if\n\t\t\t\tapplication refused for filing"}, "#text": "\n                ", "@id": "HCE87C83B069743AFBA96055ECA20EBA8"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may refund the fee or portion of\n\t\t\t\tthe fee paid under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " if no substantial work was performed on the\n\t\t\t\tapplication after the application was filed. The ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:B", "@proposed": "true"}, {"#tail": " shall have the sole\n\t\t\t\tdiscretion to refund the fee under this subparagraph. A determination by the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " concerning a refund under this subparagraph shall not be\n\t\t\t\treviewable.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "If an abbreviated application is withdrawn\n\t\t\t\tafter the application was filed, the "}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "header": {"#tail": "\n                ", "#text": "Refund of fee if\n\t\t\t\tapplication withdrawn"}, "#text": "\n                ", "@id": "H4B9012D672CA4303B83C903E73BAE9B8"}], "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Abbreviated\n\t\t\t\tapplication fee"}, "#text": "\n              ", "@id": "H230D357AE2AB4CA78389401CAFE684B1"}, {"#tail": "\n            ", "subparagraph": [{"continuation-text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, "@continuation-text-level": "subparagraph", "#text": "shall\n\t\t\t\tpay for each such generic new animal drug product the annual fee established in\n\t\t\t\t"}, "#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, "#text": "who is named as\n\t\t\t\tthe applicant in an abbreviated application or supplemental abbreviated\n\t\t\t\tapplication for a generic new animal drug product which has been submitted for\n\t\t\t\tlisting under "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "HBF8BABFF7F9443CD90ACC6B7AF65B02A", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an abbreviated application\n\t\t\t\tor supplemental abbreviated application,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after\n\t\t\t\tSeptember 1, 2008, had pending before the "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H68561D655A49415891D0E20291FC5962", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Each person\u2014"}, "#text": "\n                ", "@id": "HBC64E94FE8F444BCA593591FD6CE9E0C"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the first business\n\t\t\t\tday after the date of enactment of an appropriations Act providing for the\n\t\t\t\tcollection and obligation of fees for such fiscal year under this section;\n\t\t\t\tor"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H28FEB328F9A24FBCA7F87D4069F15086", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "January 31 of\n\t\t\t\teach year."}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "HBB3B72789FB4430E84D86E83EAD12A23", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Payment; fee due\n\t\t\t\tdate"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or is submitted for relisting under ", "@entity-type": "act", "#text": "section\n\t\t\t\t510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, {"#tail": " if the generic new animal\n\t\t\t\tdrug product has been withdrawn from listing and relisted. After such fee is\n\t\t\t\tpaid for that fiscal year, such fee shall be due each subsequent fiscal year\n\t\t\t\tthat the product remains listed, upon the later of\u2014", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}], "#text": "Such fee shall be payable for the fiscal year in which the\n\t\t\t\tgeneric new animal drug product is first submitted for listing under "}, "#text": "\n                ", "@id": "H4EC94EFD1378475F9030A9B7F15D47E2"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Such\n\t\t\t\tfee shall be paid only once for each generic new animal drug product for a\n\t\t\t\tfiscal year in which the fee is payable."}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n                ", "#text": "Limitation"}, "#text": "\n                ", "@id": "H1113245207FA452BAA99D7FDB0A89D67"}], "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Generic new\n\t\t\t\tanimal drug product fee"}, "#text": "\n              ", "@id": "H292F0DD0556348C2BD4A4CAF459EC863"}, {"#tail": "\n          ", "subparagraph": [{"continuation-text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, "@continuation-text-level": "subparagraph", "#text": "shall\n\t\t\t\tbe assessed an annual generic new animal drug sponsor fee as established under\n\t\t\t\t"}, "#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "who meets the\n\t\t\t\tdefinition of a generic new animal drug sponsor within a fiscal year;\n\t\t\t\tand"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "HE5BAE67CA7024C779C25D6F985D54864", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " an abbreviated application,\n\t\t\t\ta supplemental abbreviated application, or an investigational\n\t\t\t\tsubmission,", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "who, after\n\t\t\t\tSeptember 1, 2008, had pending before the "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "HAE59734E88004AFA8FB96A40BD7863B0", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Each person\u2014"}, "#text": "\n                ", "@id": "HFAB3D6F0FB1148B7B3B6FF05D94CAD8B"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the first business\n\t\t\t\tday after the date of enactment of an appropriations Act providing for the\n\t\t\t\tcollection and obligation of fees for such fiscal year under this section;\n\t\t\t\tor"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H8BFE74EFB6054A4D82C933E6F67FDE84", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "January 31 of\n\t\t\t\teach year."}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H81B1719E5E2E486BB415DF460ADFC447", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Payment; fee due\n\t\t\t\tdate"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Such fee shall be due each fiscal year upon the later\n\t\t\t\tof\u2014"}, "#text": "\n                ", "@id": "H869560378FCE41B1B4C7800B84CD44FE"}, {"#tail": "\n            ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for an applicant with more than 6 approved\n\t\t\t\tabbreviated applications.", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, "#text": "100 percent of the\n\t\t\t\tamount of the generic new animal drug sponsor fee published for that fiscal\n\t\t\t\tyear under "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H8A2D313AAFE4417EB45C50A49E49885E", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for an applicant with more than 1 and fewer than 7\n\t\t\t\tapproved abbreviated applications.", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, "#text": "75 percent of the\n\t\t\t\tamount of the generic new animal drug sponsor fee published for that fiscal\n\t\t\t\tyear under "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H9E91F087D5EA4A69A340F7FE21DC4EC1", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for an applicant with 1 or fewer approved abbreviated\n\t\t\t\tapplications.", "@entity-type": "act", "#text": "subsection (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, "#text": "50 percent of\n\t\t\t\tthe amount of the generic new animal drug sponsor fee published for that fiscal\n\t\t\t\tyear under "}, "enum": {"#tail": "\n                  ", "#text": "(iii)"}, "@id": "HEED90916F78141E390FF8135D5B80D4C", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n                ", "#text": "Amount of\n\t\t\t\tfee"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Each generic new animal drug sponsor shall pay only 1 such\n\t\t\t\tfee each fiscal year, as follows:"}, "#text": "\n                ", "@id": "H943A252C1AD6498AB6AD16BDE235C423"}], "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Generic new\n\t\t\t\tanimal drug sponsor fee"}, "#text": "\n              ", "@id": "HAF9F11C4335B462EB956BF648FA5FD37"}], "#text": "\n            ", "@id": "H31B6D10DD70F40038C785822E26B4746"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", ", "@entity-type": "act", "#text": "subsections (c)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:c", "@proposed": "true"}, {"#tail": ", ", "@entity-type": "act", "#text": "(d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:d", "@proposed": "true"}, {"#tail": ", and ", "@entity-type": "act", "#text": "(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:f", "@proposed": "true"}, {"#tail": ", the fees\n\t\t\t\trequired under ", "@entity-type": "act", "#text": "(g)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g", "@proposed": "true"}, {"#tail": " shall be established to generate fee revenue\n\t\t\t\tamounts as follows:", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}], "#text": "Subject to "}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Fee\n\t\t\t\tamounts"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be\n\t\t\t\t$1,832,000 for fiscal year 2014, $1,736,000 for fiscal year 2015, $1,857,000\n\t\t\t\tfor fiscal year 2016, $1,984,000 for fiscal year 2017, and $2,117,000 for\n\t\t\t\tfiscal year 2018.", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1", "@proposed": "true"}, "#text": "The total fee revenues to be\n\t\t\t\tcollected in abbreviated application fees under "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Total fee\n\t\t\t\trevenues for application fees"}, "#text": "\n              ", "@id": "HAD812F22280D4AC0A13BCE56D74F0B4E"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be\n\t\t\t\t$2,748,000 for fiscal year 2014, $2,604,000 for fiscal year 2015, $2,786,000\n\t\t\t\tfor fiscal year 2016, $2,976,000 for fiscal year 2017, and $3,175,000 for\n\t\t\t\tfiscal year 2018.", "@entity-type": "act", "#text": "subsection (a)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:2", "@proposed": "true"}, "#text": "The total fee revenues to be collected\n\t\t\t\tin generic new animal drug product fees under "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Total fee\n\t\t\t\trevenues for product fees"}, "#text": "\n              ", "@id": "HEC90CE06C8BD485AB3788327B6073DBF"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be\n\t\t\t\t$2,748,000 for fiscal year 2014, $2,604,000 for fiscal year 2015, $2,786,000\n\t\t\t\tfor fiscal year 2016, $2,976,000 for fiscal year 2017, and $3,175,000 for\n\t\t\t\tfiscal year 2018.", "@entity-type": "act", "#text": "subsection (a)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:3", "@proposed": "true"}, "#text": "The total fee revenues to be collected\n\t\t\t\tin generic new animal drug sponsor fees under "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Total fee\n\t\t\t\trevenues for sponsor fees"}, "#text": "\n              ", "@id": "H8713ADE6808141509B1D55380C8DE6A7"}], "#text": "\n            ", "@id": "HD8741F8007F344AD959F88211B4FAA2B"}, {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Annual fee\n\t\t\t\tsetting; adjustments"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish, 60 days before the start\n\t\t\t\tof each fiscal year beginning after September 30, 2008, for that fiscal year,\n\t\t\t\tabbreviated application fees, generic new animal drug sponsor fees, and generic\n\t\t\t\tnew animal drug product fees, based on the revenue amounts established under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the adjustments provided under this subsection.", "@entity-type": "act", "#text": "subsection (b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:b", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Annual fee\n\t\t\t\tsetting"}, "#text": "\n              ", "@id": "H4D61BB8E85774226B56DF3D1DDDC6675"}, {"#tail": "\n            ", "@id": "H1F75BB28254A48A2A5048447D8580D9F", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Workload\n\t\t\t\tadjustment"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The fee revenues shall be adjusted each fiscal year\n\t\t\t\tafter fiscal year 2014 to reflect changes in review workload. With respect to\n\t\t\t\tsuch adjustment:"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " based on a weighted average of the change\n\t\t\t\tin the total number of abbreviated applications for generic new animal drugs,\n\t\t\t\tmanufacturing supplemental abbreviated applications for generic new animal\n\t\t\t\tdrugs, investigational generic new animal drug study submissions, and\n\t\t\t\tinvestigational generic new animal drug protocol submissions submitted to the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ". The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall publish in the Federal Register the fees\n\t\t\t\tresulting from this adjustment and the supporting methodologies.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "This adjustment\n\t\t\t\tshall be determined by the "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H689970C6CED6435B9749CCC681F40016", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:b", "@proposed": "true"}, "#text": "Under no\n\t\t\t\tcircumstances shall this workload adjustment result in fee revenues for a\n\t\t\t\tfiscal year that are less than the fee revenues for that fiscal year\n\t\t\t\testablished in "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HDE7ECC541C78478EBD4FC8F0DF836522", "#text": "\n                "}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, in addition\n\t\t\t\tto other adjustments under this subsection, further increase the fees under\n\t\t\t\tthis section, if such an adjustment is necessary, to provide for up to 3 months\n\t\t\t\tof operating reserves of carryover user fees for the process for the review of\n\t\t\t\tabbreviated applications for generic new animal drugs for the first 3 months of\n\t\t\t\tfiscal year 2019. If the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " has carryover balances\n\t\t\t\tfor the process for the review of abbreviated applications for generic new\n\t\t\t\tanimal drugs in excess of 3 months of such operating reserves, then this\n\t\t\t\tadjustment shall not be made. If this adjustment is necessary, then the\n\t\t\t\trationale for the amount of the increase shall be contained in the annual\n\t\t\t\tnotice setting fees for fiscal year 2018.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "For fiscal year 2018, the "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Final year\n\t\t\t\tadjustment"}, "#text": "\n              ", "@id": "H6406503B176542219F9668392B2B87BA"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "The\n\t\t\t\ttotal amount of fees charged, as adjusted under this subsection, for a fiscal\n\t\t\t\tyear may not exceed the total costs for such fiscal year for the resources\n\t\t\t\tallocated for the process for the review of abbreviated applications for\n\t\t\t\tgeneric new animal drugs."}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n              ", "#text": "Limit"}, "#text": "\n              ", "@id": "H6E42A87E1319463EA1CF3582EB2AC68E"}], "#text": "\n            ", "@id": "H9407CA8ACDEC4482941CB032A9A2DA99"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall grant a waiver from or a reduction\n\t\t\t\tof 1 or more fees assessed under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " where the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": " finds that\n\t\t\t\tthe generic new animal drug is intended solely to provide for a minor use or\n\t\t\t\tminor species indication.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n            ", "#text": "Fee waiver or\n\t\t\t\treduction"}, "#text": "\n            ", "@id": "H864F950F444041C18AD7506536F9BD52"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be\n\t\t\t\tconsidered incomplete and shall not be accepted for filing by the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": "\n\t\t\t\tuntil all fees owed by such person have been paid. An investigational\n\t\t\t\tsubmission for a generic new animal drug that is submitted by a person subject\n\t\t\t\tto fees under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall be considered incomplete and shall not be\n\t\t\t\taccepted for review by the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": " until all fees owed by such person have\n\t\t\t\tbeen paid. The ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may discontinue review of any abbreviated application\n\t\t\t\tfor a generic new animal drug, supplemental abbreviated application for a\n\t\t\t\tgeneric new animal drug, or investigational submission for a generic new animal\n\t\t\t\tdrug from a person if such person has not submitted for payment all fees owed\n\t\t\t\tunder this section by 30 days after the date upon which they are due.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "An abbreviated application for a generic new\n\t\t\t\tanimal drug submitted by a person subject to fees under "}, "enum": {"#tail": "\n            ", "#text": "(e)"}, "header": {"#tail": "\n            ", "#text": "Effect of\n\t\t\t\tfailure To pay fees"}, "#text": "\n            ", "@id": "HCFD36AB449964A31901B19FC71D8A917"}, {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(f)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Assessment of\n\t\t\t\tfees"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " for a fiscal year beginning after\n\t\t\t\tfiscal year 2008 unless appropriations for salaries and expenses of the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": " for such fiscal year (excluding the amount of fees\n\t\t\t\tappropriated for such fiscal year) are equal to or greater than the amount of\n\t\t\t\tappropriations for the salaries and expenses of the ", "@entity-type": "federal-body", "#text": "Food\n\t\t\t\tand Drug Administration", "@entity-id": "7524"}, {"#tail": " for the fiscal year 2003 (excluding the amount of fees\n\t\t\t\tappropriated for such fiscal year) multiplied by the adjustment factor\n\t\t\t\tapplicable to the fiscal year involved.", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t\tAdministration", "@entity-id": "7524"}], "#text": "Fees\n\t\t\t\tmay not be assessed under "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Limitation"}, "#text": "\n              ", "@id": "H70B83D33C1E74C50A73360F48126D343"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " does not assess fees under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " during any portion of a\n\t\t\t\tfiscal year because of ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": " and if at a later date in such fiscal year\n\t\t\t\tthe ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:f/p:1", "@proposed": "true"}, {"#tail": " may assess such fees, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may assess and collect such\n\t\t\t\tfees, without any modification in the rate, for abbreviated applications,\n\t\t\t\tgeneric new animal drug sponsors, and generic new animal drug products at any\n\t\t\t\ttime in such fiscal year notwithstanding the provisions of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": "\n\t\t\t\trelating to the date fees are to be paid.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}], "#text": "If\n\t\t\t\tthe "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Authority"}, "#text": "\n              ", "@id": "H57EC6C9E191F42D5B13F470E89AAA13D"}], "#text": "\n            ", "@id": "H7F6BBBB68F9042DA92440C4A3085C62B"}, {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(g)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Crediting and\n\t\t\t\tavailability of fees"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", fees authorized under\n\t\t\t\t", "@entity-type": "act", "#text": "paragraph (2)(C)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:C", "@proposed": "true"}, {"#tail": " shall be collected and available for obligation only to the\n\t\t\t\textent and in the amount provided in advance in appropriations Acts. Such fees\n\t\t\t\tare authorized to be appropriated to remain available until expended. Such sums\n\t\t\t\tas may be necessary may be transferred from the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": "\n\t\t\t\tsalaries and expenses appropriation account without fiscal year limitation to\n\t\t\t\tsuch appropriation account for salary and expenses with such fiscal year\n\t\t\t\tlimitation. The sums transferred shall be available solely for the process for\n\t\t\t\tthe review of abbreviated applications for generic new animal drugs.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Subject to "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n              ", "@id": "H094786723DBC4622A17D6D91F69DD5FB"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", shall be collected and available in each fiscal year in an\n\t\t\t\tamount not to exceed the amount specified in appropriation Acts, or otherwise\n\t\t\t\tmade available for obligation for such fiscal year; and", "@entity-type": "act", "#text": "subparagraph (C)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:C", "@proposed": "true"}, "#text": "subject to\n\t\t\t\t"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "HD7735760BF62412D9E17B44BEC8ED821", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to be\n\t\t\t\tengaged in such process) over such costs, excluding costs paid from fees\n\t\t\t\tcollected under this section, for fiscal year 2008 multiplied by the adjustment\n\t\t\t\tfactor.", "@entity-type": "federal-body", "#text": "Department of Health and Human Services", "@entity-id": "7500"}, "#text": "shall be\n\t\t\t\tavailable to defray increases in the costs of the resources allocated for the\n\t\t\t\tprocess for the review of abbreviated applications for generic new animal drugs\n\t\t\t\t(including increases in such costs for an additional number of full-time\n\t\t\t\tequivalent positions in the "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "HDA71F68D65F249EB9241D44FFC3D3D20", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The fees authorized by this section\u2014"}, "#text": "\n                ", "@id": "HA909FFA8092D4B08BD39CD5897FD3D6F"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; or", "@entity-type": "act", "#text": "subparagraph (A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii", "@proposed": "true"}, "#text": "are not more than\n\t\t\t\t3 percent below the level specified in "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "HD5BBFA46F0144DA3B8C84F882DAF05BB", "#text": "\n                  "}, {"#tail": "\n              ", "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", and fees assessed for the\n\t\t\t\tfiscal year following the subsequent fiscal year are decreased by the amount in\n\t\t\t\texcess of 3 percent by which such costs fell below the level specified in\n\t\t\t\t", "@entity-type": "act", "#text": "subparagraph (A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii", "@proposed": "true"}, {"#tail": "; and", "@entity-type": "act", "#text": "subparagraph (A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii", "@proposed": "true"}], "#text": "are more than 3 percent\n\t\t\t\tbelow the level specified in "}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@display-inline": "yes-display-inline", "#text": "\n                    ", "@id": "H8204153DAC19440E9D0AB2F8A6443F6C", "@commented": "no"}, {"@indent": "up1", "#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subparagraph (A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii", "@proposed": "true"}, "#text": "such costs are not more than 5 percent\n\t\t\t\tbelow the level specified in "}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "#text": "\n                    ", "@id": "HD595FB0A36F64BAB9CAEC4E94C8E7777"}], "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "HB8169292FAD74F818FEBBB88A26EE09C", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Compliance"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be considered to have met the requirements of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " in any fiscal year if the costs funded by appropriations and allocated\n\t\t\t\tfor the process for the review of abbreviated applications for generic new\n\t\t\t\tanimal drugs\u2014", "@entity-type": "act", "#text": "subparagraph\n\t\t\t\t(A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii", "@proposed": "true"}], "#text": "The\n\t\t\t\t"}, "#text": "\n                ", "@id": "HCFC504AC99354FC2AA08F8202EB9B668"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " in accordance with authority provided in advance in a prior year\n\t\t\t\tappropriations Act.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Payment of fees authorized under this section for\n\t\t\t\ta fiscal year, prior to the due date for such fees, may be accepted by the\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n                ", "#text": "Provision for\n\t\t\t\tearly payments"}, "#text": "\n                ", "@id": "H300E4C6FCE184A5AA0CEA974C309A200"}], "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Collections and\n\t\t\t\tappropriation acts"}, "#text": "\n              ", "@id": "HEE7D47D882D94613975DF16B27505A39"}, {"continuation-text": {"#tail": "\n            ", "@continuation-text-level": "paragraph", "#text": "as\n\t\t\t\tadjusted to reflect adjustments in the total fee revenues made under this\n\t\t\t\tsection and changes in the total amounts collected by abbreviated application\n\t\t\t\tfees, generic new animal drug sponsor fees, and generic new animal drug product\n\t\t\t\tfees."}, "#tail": "\n            ", "@id": "HF34B4C82B13F4ADDBE217EF25277D5D9", "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Authorization of\n\t\t\t\tappropriations"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "\n                ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n              ", "@entity-type": "auth-auth-approp", "#text": "There are authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": "\u2014", "#text": "for fees\n\t\t\t\tunder this section", "@name": "purpose"}}}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "#text": "\n                ", "@id": "H7DDFA8FA06BA45CEB14B579F63951387", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n\t\t\t\t\t\t\t", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$7,328,000 for\n\t\t\t\tfiscal year 2014", "@amount": "7328000", "@year": "2014"}, "#text": "\n                    "}, "@entity-type": "auth-auth-approp", "enum": {"#tail": "\n                ", "#text": "(A)"}, "#text": "\n                  "}}, {"#tail": "\n              ", "#text": "\n                ", "@id": "HC0B68BCBA7D94F29A7ECE2C02BDDCA71", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n\t\t\t\t\t\t\t", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$6,944,000 for\n\t\t\t\tfiscal year 2015", "@amount": "6944000", "@year": "2015"}, "#text": "\n                    "}, "@entity-type": "auth-auth-approp", "enum": {"#tail": "\n                ", "#text": "(B)"}, "#text": "\n                  "}}, {"#tail": "\n              ", "#text": "\n                ", "@id": "HF2A8AF4AE97A42A0927A8D82A50C2526", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n\t\t\t\t\t\t\t", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$7,429,000 for\n\t\t\t\tfiscal year 2016", "@amount": "7429000", "@year": "2016"}, "#text": "\n                    "}, "@entity-type": "auth-auth-approp", "enum": {"#tail": "\n                ", "#text": "(C)"}, "#text": "\n                  "}}, {"#tail": "\n              ", "#text": "\n                ", "@id": "H4FC648CDAA29434BA21B0B79C7E4790D", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n\t\t\t\t\t\t\t", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": "; and", "#text": "$7,936,000 for\n\t\t\t\tfiscal year 2017", "@amount": "7936000", "@year": "2017"}, "#text": "\n                    "}, "@entity-type": "auth-auth-approp", "enum": {"#tail": "\n                ", "#text": "(D)"}, "#text": "\n                  "}}, {"#tail": "\n              ", "#text": "\n                ", "@id": "HFC9B9653934D4C0EB9622BC5F52F0B60", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n\t\t\t\t\t\t\t", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "$8,467,000 for\n\t\t\t\tfiscal year 2018", "@amount": "8467000", "@year": "2018"}, "#text": "\n                    "}, "@entity-type": "auth-auth-approp", "enum": {"#tail": "\n                ", "#text": "(E)"}, "#text": "\n                  "}}]}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " for the fiscal years 2014 through 2017, the\n\t\t\t\texcess amount shall be credited to the appropriation account of the ", "@entity-type": "act", "#text": "paragraph (3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:3", "@proposed": "true"}, {"#tail": " as provided in ", "@entity-type": "federal-body", "#text": "Food and\n\t\t\t\tDrug Administration", "@entity-id": "7524"}, {"#tail": ", and shall be subtracted from\n\t\t\t\tthe amount of fees that would otherwise be authorized to be collected under\n\t\t\t\tthis section pursuant to appropriation Acts for fiscal year 2018.", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:1", "@proposed": "true"}], "#text": "If\n\t\t\t\tthe sum of the cumulative amount of fees collected under this section for the\n\t\t\t\tfiscal years 2014 through 2016 and the amount of fees estimated to be collected\n\t\t\t\tunder this section for fiscal year 2017 exceeds the cumulative amount\n\t\t\t\tappropriated under "}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n              ", "#text": "Offset"}, "#text": "\n              ", "@id": "H8D339FEAA30A48F7BF92DD69BF109300"}], "#text": "\n            ", "@id": "HDC69D610460840299F5205ACFDDEE3CB"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " does not receive\n\t\t\t\tpayment of a fee assessed under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " within 30 days after it is due,\n\t\t\t\tsuch fee shall be treated as a claim of the United States Government subject to\n\t\t\t\t", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": ".", "@entity-type": "uscode", "#text": "subchapter II of ", "external-xref": {"#tail": " of title 31, United States Code", "@parsable-cite": "usc-chapter/31/37", "#text": "chapter 37", "@legal-doc": "usc-chapter"}, "@value": "usc-chapter/31/37/II"}], "#text": "In any case where the "}, "enum": {"#tail": "\n            ", "#text": "(h)"}, "header": {"#tail": "\n            ", "#text": "Collection of\n\t\t\t\tunpaid fees"}, "#text": "\n            ", "@id": "H6C3815FE5A3442FB84117BAE9FBFA264"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or for a refund of any fee\n\t\t\t\tcollected in accordance with ", "@entity-type": "act", "#text": "subsection (d)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:d", "@proposed": "true"}, {"#tail": ", a person shall submit to the\n\t\t\t\t", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:a", "@proposed": "true"}, {"#tail": " a written request for such waiver, reduction, or refund not later\n\t\t\t\tthan 180 days after such fee is due.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "To qualify for consideration\n\t\t\t\tfor a waiver or reduction under "}, "enum": {"#tail": "\n            ", "#text": "(i)"}, "header": {"#tail": "\n            ", "#text": "Written requests\n\t\t\t\tfor waivers, reductions, and refunds"}, "#text": "\n            ", "@id": "H5C8565465A18406299D28A78AD03E10D"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", for officers,\n\t\t\t\temployees, and advisory committees not engaged in the process of the review of\n\t\t\t\tabbreviated applications for generic new animal drugs, be reduced to offset the\n\t\t\t\tnumber of officers, employees, and advisory committees so engaged.", "@entity-type": "federal-body", "#text": "Department of Health and Human Services", "@entity-id": "7500"}, "#text": "This\n\t\t\t\tsection may not be construed to require that the number of full-time equivalent\n\t\t\t\tpositions in the "}, "enum": {"#tail": "\n            ", "#text": "(j)"}, "header": {"#tail": "\n            ", "#text": "Construction"}, "#text": "\n            ", "@id": "H7ED1563D16614BF1A7FABA427881C402"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ":", "@entity-type": "act", "#text": "section 742", "@value": "Federal Food, Drug, and Cosmetic Act/s:742"}, "#text": "In\n\t\t\t\tthis section and "}, "enum": {"#tail": "\n            ", "#text": "(k)"}, "header": {"#tail": "\n            ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "quote": [{"#tail": " and\n\t\t\t\t", "#text": "abbreviated application for a generic new animal drug"}, {"#tail": " mean an abbreviated application for the\n\t\t\t\tapproval of any generic new animal drug submitted under ", "#text": "abbreviated application"}], "#text": "The terms\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ". Such\n\t\t\t\tterm does not include a supplemental abbreviated application for a generic new\n\t\t\t\tanimal drug.", "@entity-type": "act", "#text": "section 512(b)(2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2"}}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Abbreviated\n\t\t\t\tapplication for a generic new animal drug"}, "#text": "\n              ", "@id": "H120E4EC35AFB4EFF9D7AC5A797A13ADB"}, {"#tail": "\n            ", "@id": "HD6EBB8C69F3045B1B7F9A76DA61D487D", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Adjustment\n\t\t\t\tfactor"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " applicable to a\n\t\t\t\tfiscal year is the Consumer Price Index for all urban consumers (all items;\n\t\t\t\tUnited States city average) for October of the preceding fiscal year divided\n\t\t\t\tby\u2014", "#text": "adjustment factor"}, "#text": "The term "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", such Index for October 2002; and", "@entity-type": "act", "#text": "subsection (f)(1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:f/p:1", "@proposed": "true"}, "#text": "for purposes of\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H3032D3E5B0B84439BAED10E941E4F193", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", such Index for October 2007.", "@entity-type": "act", "#text": "subsection (g)(2)(A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii", "@proposed": "true"}, "#text": "for purposes of\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HAF551974FBB1405794FA4C623D5C86F9", "#text": "\n                "}]}, {"#tail": "\n            ", "@id": "H80B90903A9DE44ADB6D38700C7AB625B", "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Costs of\n\t\t\t\tresources allocated for the process for the review of abbreviated applications\n\t\t\t\tfor generic new animal drugs"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means the expenses in connection with the\n\t\t\t\tprocess for the review of abbreviated applications for generic new animal drugs\n\t\t\t\tfor\u2014", "#text": "costs of resources\n\t\t\t\tallocated for the process for the review of abbreviated applications for\n\t\t\t\tgeneric new animal drugs"}, "#text": "The term "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", contractors of the Food and Drug\n\t\t\t\tAdministration, advisory committees consulted with respect to the review of\n\t\t\t\tspecific abbreviated applications, supplemental abbreviated applications, or\n\t\t\t\tinvestigational submissions, and costs related to such officers, employees,\n\t\t\t\tcommittees, and contractors, including costs for travel, education, and\n\t\t\t\trecruitment and other personnel activities;", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "officers and\n\t\t\t\temployees of the "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H6E34D3909FB04F6FA25AB230CE79D796", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "management of\n\t\t\t\tinformation, and the acquisition, maintenance, and repair of computer\n\t\t\t\tresources;"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HAA2E53BA0A3A4CBFAFE69A4DCF84D258", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "leasing,\n\t\t\t\tmaintenance, renovation, and repair of facilities and acquisition, maintenance,\n\t\t\t\tand repair of fixtures, furniture, scientific equipment, and other necessary\n\t\t\t\tmaterials and supplies; and"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "H5C13E0F0BB894FFA9A8EC03DC6C26FA3", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "collecting fees\n\t\t\t\tunder this section and accounting for resources allocated for the review of\n\t\t\t\tabbreviated applications, supplemental abbreviated applications, and\n\t\t\t\tinvestigational submissions."}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "H9F222C76295B48F78B4B4D0E5E6D0231", "#text": "\n                "}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": " means, with respect\n\t\t\t\tto a generic new animal drug product, a finished dosage form which is approved\n\t\t\t\tfor administration to an animal without substantial further manufacturing. Such\n\t\t\t\tterm includes generic new animal drug products intended for mixing in animal\n\t\t\t\tfeeds.", "#text": "final dosage form"}, "#text": "The term "}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n              ", "#text": "Final dosage\n\t\t\t\tform"}, "#text": "\n              ", "@id": "H754625C3FA7A4F9FB6759FBBFD236DD6"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": " means a\n\t\t\t\tnew animal drug that is the subject of an abbreviated application.", "#text": "generic new animal drug"}, "#text": "The term "}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "header": {"#tail": "\n              ", "#text": "Generic new\n\t\t\t\tanimal drug"}, "#text": "\n              ", "@id": "HEB783EFC67024444A00D1AB2E3B6F056"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "term": {"#tail": " means each specific strength or potency of a particular active\n\t\t\t\tingredient or ingredients in final dosage form marketed by a particular\n\t\t\t\tmanufacturer or distributor, which is uniquely identified by the labeler code\n\t\t\t\tand product code portions of the national drug code, and for which an\n\t\t\t\tabbreviated application for a generic new animal drug or a supplemental\n\t\t\t\tabbreviated application has been approved.", "#text": "generic new animal drug\n\t\t\t\tproduct"}, "#text": "The term "}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "header": {"#tail": "\n              ", "#text": "Generic new\n\t\t\t\tanimal drug product"}, "#text": "\n              ", "@id": "HF8A2E1116AA141389FB55D4238031D32"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or a person who has\n\t\t\t\tsubmitted an investigational submission for a generic new animal drug that has\n\t\t\t\tnot been terminated or otherwise rendered inactive by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "term": {"#tail": " means either an applicant named in an abbreviated application\n\t\t\t\tfor a generic new animal drug that has not been withdrawn by the applicant and\n\t\t\t\tfor which approval has not been withdrawn by the ", "#text": "generic new animal drug\n\t\t\t\tsponsor"}, "#text": "The term "}, "enum": {"#tail": "\n              ", "#text": "(7)"}, "header": {"#tail": "\n              ", "#text": "Generic new\n\t\t\t\tanimal drug sponsor"}, "#text": "\n              ", "@id": "H3CA15F03F84D482AB80684A2095CEEE8"}, {"#tail": "\n            ", "@id": "HCA826D5DB86B4D61B53E2EB0B6176F54", "enum": {"#tail": "\n              ", "#text": "(8)"}, "header": {"#tail": "\n              ", "#text": "Investigational\n\t\t\t\tsubmission for a generic new animal drug"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "quote": {"#tail": " mean\u2014", "#text": "investigational submission"}, "term": {"#tail": " and\n\t\t\t\t", "#text": "investigational submission for a generic new animal drug"}, "#text": "The terms\n\t\t\t\t"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for a generic new\n\t\t\t\tanimal drug intended to be the subject of an abbreviated application or a\n\t\t\t\tsupplemental abbreviated application; or", "@entity-type": "act", "#text": "section 512(j)", "@value": "Federal Food, Drug, and Cosmetic Act/s:512/ss:j"}, "#text": "the filing of a\n\t\t\t\tclaim for an investigational exemption under "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H67F5CA7F9FAF4CD584EC2E81836746E1", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to evaluate the safety or\n\t\t\t\teffectiveness of a generic new animal drug in the event of the filing of an\n\t\t\t\tabbreviated application or supplemental abbreviated application for such\n\t\t\t\tdrug.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the submission of\n\t\t\t\tinformation for the purpose of enabling the "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H170F386295074CC3B6D7528956D63244", "#text": "\n                "}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ").", "@entity-type": "act", "#text": "section 735(11)", "@value": "Federal Food, Drug, and Cosmetic Act/s:735/p:11"}, "term": {"#tail": " includes an affiliate thereof (as such term is defined\n\t\t\t\tin ", "#text": "person"}, "#text": "The\n\t\t\t\tterm "}, "enum": {"#tail": "\n              ", "#text": "(9)"}, "header": {"#tail": "\n              ", "#text": "Person"}, "#text": "\n              ", "@id": "H9E49921A14D04A00BD2F836AAFD6F4C6"}, {"#tail": "\n            ", "@id": "H1EE9726CF3CA43C19462577574070FA6", "enum": {"#tail": "\n              ", "#text": "(10)"}, "header": {"#tail": "\n              ", "#text": "Process for the\n\t\t\t\treview of abbreviated applications for generic new animal\n\t\t\t\tdrugs"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " with respect to the review of abbreviated applications,\n\t\t\t\tsupplemental abbreviated applications, and investigational submissions:", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "term": {"#tail": " means the following activities\n\t\t\t\tof the ", "#text": "process for the review of abbreviated\n\t\t\t\tapplications for generic new animal drugs"}, "#text": "The term "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The activities\n\t\t\t\tnecessary for the review of abbreviated applications, supplemental abbreviated\n\t\t\t\tapplications, and investigational submissions."}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HEF18F09070494C80B10A93433628127D", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The issuance of\n\t\t\t\taction letters which approve abbreviated applications or supplemental\n\t\t\t\tabbreviated applications or which set forth in detail the specific deficiencies\n\t\t\t\tin abbreviated applications, supplemental abbreviated applications, or\n\t\t\t\tinvestigational submissions and, where appropriate, the actions necessary to\n\t\t\t\tplace such applications, supplemental applications, or submissions in condition\n\t\t\t\tfor approval."}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H1322BB8F8F2B431E8F682B8FC7DDE0DA", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " review of pending abbreviated applications, supplemental\n\t\t\t\tabbreviated applications, and investigational submissions.", "@entity-type": "federal-body", "#text": "Secretary\u2019s", "@entity-id": "7500"}, "#text": "The inspection of\n\t\t\t\tgeneric new animal drug establishments and other facilities undertaken as part\n\t\t\t\tof the "}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "H5D05E0823D5146E69268399DDD135D8F", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Monitoring of\n\t\t\t\tresearch conducted in connection with the review of abbreviated applications,\n\t\t\t\tsupplemental abbreviated applications, and investigational submissions."}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "HECC80E89B43541D999917A79AE20DBC9", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "The development of\n\t\t\t\tregulations and policy related to the review of abbreviated applications,\n\t\t\t\tsupplemental abbreviated applications, and investigational submissions."}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@id": "H3036CAC4DBD544FE94904E95EC53B1D2", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Development of\n\t\t\t\tstandards for products subject to review."}, "enum": {"#tail": "\n                ", "#text": "(F)"}, "@id": "H86252C842D9946F4BC2374B92F53FC00", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Meetings between\n\t\t\t\tthe agency and the generic new animal drug sponsor."}, "enum": {"#tail": "\n                ", "#text": "(G)"}, "@id": "H0FDF97F42E524525842B7995E42A54E4", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Review of\n\t\t\t\tadvertising and labeling prior to approval of an abbreviated application or\n\t\t\t\tsupplemental abbreviated application, but not after such application has been\n\t\t\t\tapproved."}, "enum": {"#tail": "\n                ", "#text": "(H)"}, "@id": "HF68BE7A6CB8742E49E8A6DD7B86F72BB", "#text": "\n                "}]}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "quote": [{"#tail": " and ", "#text": "supplemental abbreviated application for a generic new animal\n\t\t\t\tdrug"}, {"#tail": " mean a\n\t\t\t\trequest to the Secretary to approve a change in an approved abbreviated\n\t\t\t\tapplication.", "#text": "supplemental abbreviated application"}], "#text": "The terms\n\t\t\t\t"}, "enum": {"#tail": "\n              ", "#text": "(11)"}, "header": {"#tail": "\n              ", "#text": "Supplemental\n\t\t\t\tabbreviated application for generic new animal drug"}, "#text": "\n              ", "@id": "H2A7C323908284A5A8119EB544BB6F4C2"}], "#text": "\n            ", "@id": "H8E0FE28B1AE24308859B662547338AE6"}], "#text": "\n          ", "@id": "HB6BC04B1B42240D4BABE5DE7FF24B062"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t", "@id": "H5BB9737F08F84967B2CBBFF83E8FD153"}, "#text": "\n      ", "@id": "H8778152F022441D19514095A956B1938"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\n\t\t\t to read as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section\n\t\t\t 742 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:742"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/379j-22", "#text": "21 U.S.C. 379j\u201322", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Reauthorization;\n\t\t\t reporting requirements"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "742."}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Reauthorization;\n\t\t\t\treporting requirements"}, "subsection": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall prepare and submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", and the ", "@entity-type": "committee", "#text": "Committee on Health,\n\t\t\t\tEducation, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " a report concerning the progress of\n\t\t\t\tthe ", "@entity-type": "committee", "#text": "Committee on Energy and\n\t\t\t\tCommerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": " in achieving the goals identified in the\n\t\t\t\tletters described in ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " toward expediting the generic new animal drug development\n\t\t\t\tprocess and the review of abbreviated applications for generic new animal\n\t\t\t\tdrugs, supplemental abbreviated applications for generic new animal drugs, and\n\t\t\t\tinvestigational submissions for generic new animal drugs during such fiscal\n\t\t\t\tyear.", "@entity-type": "act", "#text": "section 1(b) of the Animal Generic Drug User Fee\n\t\t\t\tAmendments of 2013", "@value": "Animal Generic Drug User Fee Amendments of 2013/s:1/ss:b", "@proposed": "true"}], "#text": "Beginning with fiscal year 2014, not later than 120 days\n\t\t\t\tafter the end of each fiscal year during which fees are collected under this\n\t\t\t\tpart, the "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "Performance\n\t\t\t\treports"}, "#text": "\n            ", "@id": "H6BB716F607734599B5A4ECC0F650C369"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall prepare and submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on Health,\n\t\t\t\tEducation, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " a report on the implementation of the\n\t\t\t\tauthority for such fees during such fiscal year and the use, by the ", "@entity-type": "committee", "#text": "Committee on Energy and\n\t\t\t\tCommerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": ", of the fees collected during such fiscal year for which\n\t\t\t\tthe report is made.", "@entity-type": "federal-body", "#text": "Food and\n\t\t\t\tDrug Administration", "@entity-id": "7524"}], "#text": "Beginning with fiscal year 2014, not later than 120 days\n\t\t\t\tafter the end of each fiscal year during which fees are collected under this\n\t\t\t\tpart, the "}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Fiscal\n\t\t\t\treport"}, "#text": "\n            ", "@id": "H4B1EEB71DC4B40349DF9A98F60FD3F09"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall make the reports required under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and ", "@entity-type": "act", "#text": "subsections (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:a", "@proposed": "true"}, {"#tail": " available to the public on the Internet Web site of the\n\t\t\t\t", "@entity-type": "act", "#text": "(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:b", "@proposed": "true"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Public\n\t\t\t\tavailability"}, "#text": "\n            ", "@id": "H64B53659F75F48B1A06DDCFE8F235149"}, {"#tail": "\n        ", "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Reauthorization"}, "paragraph": [{"#tail": "\n            ", "@id": "H311D49594CB74992B98CB3F20F813539", "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Consultation"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " with respect to the goals,\n\t\t\t\tand plans for meeting the goals, for the process for the review of abbreviated\n\t\t\t\tapplications for generic new animal drugs for the first 5 fiscal years after\n\t\t\t\tfiscal year 2018, and for the reauthorization of this part for such fiscal\n\t\t\t\tyears, the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": " shall consult with\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In\n\t\t\t\tdeveloping recommendations to present to "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tEnergy and Commerce of the House of Representatives"}, "#text": "the "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H4B5A32A4C1D7415CBD2F9C698F4BC644", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "committee", "#text": "Committee on\n\t\t\t\tHealth, Education, Labor, and Pensions of the Senate", "@entity-id": "SSHR00"}, "#text": "the "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HF0DF330FFE0A46108279674F52C53C99", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "scientific and\n\t\t\t\tacademic experts;"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "HD7E44EE6B69F4DF588CF75990D719659", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "veterinary\n\t\t\t\tprofessionals;"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "H66C261A008D1430B979BBAC6B35C16AF", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "representatives of\n\t\t\t\tpatient and consumer advocacy groups; and"}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@id": "H55682F42F5E34B2EB92ECDBD1637213D", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the regulated\n\t\t\t\tindustry."}, "enum": {"#tail": "\n                ", "#text": "(F)"}, "@id": "HCAC21372F4A847CCB66E6884F683ABE7", "#text": "\n                "}]}, {"#tail": "\n            ", "@id": "H5A6FCCB2C04442B8B5B2936B50637F5A", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Prior public\n\t\t\t\tinput"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Prior to beginning negotiations with the regulated industry\n\t\t\t\ton the reauthorization of this part, the "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "publish a notice\n\t\t\t\tin the Federal Register requesting public input on the reauthorization;"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HFE4891C598654DF8BF6EDB16F08710CB", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:a", "@proposed": "true"}, "#text": "hold a public\n\t\t\t\tmeeting at which the public may present its views on the reauthorization,\n\t\t\t\tincluding specific suggestions for changes to the goals referred to in\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H3A268B48C3C24989B124E6FE546AE501", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "provide a period\n\t\t\t\tof 30 days after the public meeting to obtain written comments from the public\n\t\t\t\tsuggesting changes to this part; and"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "H8045FAACB65E4DE58F1A45143EC41598", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "publish the\n\t\t\t\tcomments on the Food and Drug Administration\u2019s Internet Web site."}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "H390D8D1A8BF4491ABA3B4F564D7F86D9", "#text": "\n                "}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall hold discussions\n\t\t\t\twith representatives of veterinary, patient, and consumer advocacy groups to\n\t\t\t\tcontinue discussions of their views on the reauthorization and their\n\t\t\t\tsuggestions for changes to this part as expressed under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:2", "@proposed": "true"}], "#text": "Not less frequently than once every 4 months during\n\t\t\t\tnegotiations with the regulated industry, the "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Periodic\n\t\t\t\tconsultation"}, "#text": "\n              ", "@id": "H3C03244C828D4331B7A965E8C982B043"}, {"#tail": "\n            ", "@id": "HDED596489D314167B331FD137A7A4849", "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n              ", "#text": "Public review of\n\t\t\t\trecommendations"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "After negotiations with the regulated industry,\n\t\t\t\tthe "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to the congressional committees\n\t\t\t\tspecified in such paragraph;", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:1", "@proposed": "true"}, "#text": "present the\n\t\t\t\trecommendations developed under "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H0DFDB388AD504C448E06CEDF88971C59", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "publish such\n\t\t\t\trecommendations in the Federal Register;"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H2C637FFE30894D00B09F10F6F7AB6528", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "provide for a\n\t\t\t\tperiod of 30 days for the public to provide written comments on such\n\t\t\t\trecommendations;"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "H5D8609EAAAED4EC8BD245A129CAEA5E1", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "hold a meeting at\n\t\t\t\twhich the public may present its views on such recommendations; and"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "HE23A086F0435417998DC658B8EB3D89B", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "after\n\t\t\t\tconsideration of such public views and comments, revise such recommendations as\n\t\t\t\tnecessary."}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@id": "HBB9DEC3AF0B1469DB3F13D17860F837F", "#text": "\n                "}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "\n\t\t\t\tshall transmit to ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " the revised recommendations under ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": ", a\n\t\t\t\tsummary of the views and comments received under such paragraph, and any\n\t\t\t\tchanges made to the recommendations in response to such views and\n\t\t\t\tcomments.", "@entity-type": "act", "#text": "paragraph (4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:4", "@proposed": "true"}], "#text": "Not later than January 15, 2018, the "}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "header": {"#tail": "\n              ", "#text": "Transmittal of\n\t\t\t\trecommendations"}, "#text": "\n              ", "@id": "H18B34F9BBB1144198AA711A42419292B"}, {"#tail": "\n          ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " to ", "@entity-type": "act", "#text": "paragraphs (1) through (5)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:1..5", "@proposed": "true"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": " shall make publicly\n\t\t\t\tavailable, on the Internet Web site of the Food and Drug Administration,\n\t\t\t\tminutes of all negotiation meetings conducted under this subsection between the\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the regulated industry.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Before presenting the recommendations developed\n\t\t\t\tunder "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "Public\n\t\t\t\tavailability"}, "#text": "\n                ", "@id": "H3BFF6B76BA8C41B8876E976C2BA74CAF"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall summarize any substantive\n\t\t\t\tproposal made by any party to the negotiations as well as significant\n\t\t\t\tcontroversies or differences of opinion during the negotiations and their\n\t\t\t\tresolution.", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:6/sp:A", "@proposed": "true"}, "#text": "The\n\t\t\t\tminutes described under "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Content"}, "#text": "\n                ", "@id": "H1742227628DE4F73A106C73183FAA9F0"}], "enum": {"#tail": "\n              ", "#text": "(6)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Minutes of\n\t\t\t\tnegotiation meetings"}, "#text": "\n              ", "@id": "H7666F373573D42B3AC12E172DC90EED3"}], "#text": "\n            ", "@id": "H2803AE6B40B048ACA6630911188C45B6"}], "#text": "\n          ", "@id": "H8A7E177F1B9846EBBBDBCAFC776BF2A5"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t", "@id": "H276E6626F2E548E181788316DBB62C01"}, "#text": "\n      ", "@id": "H49B2210CFEB94A129520F983DB276AE5"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", as in effect on the day before the date\n\t\t\t of enactment of this Act, shall continue to be in effect with respect to\n\t\t\t abbreviated applications for a generic new animal drug and supplemental\n\t\t\t abbreviated applications for a generic new animal drug (as defined in such part\n\t\t\t as of such day) that on or after October 1, 2008, but before October 1, 2013,\n\t\t\t were accepted by the ", "@entity-type": "act", "#text": "part 5 of subchapter C of chapter VII of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5"}, {"#tail": " for filing with respect to\n\t\t\t assessing and collecting any fee required by such part for a fiscal year prior\n\t\t\t to fiscal year 2014.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Notwithstanding the\n\t\t\t amendments made by this Act, ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Savings\n\t\t\t clause"}, "#text": "\n      ", "@id": "H95CB907BAA5F491EBF6A2935FAF022F1"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", as amended by this\n\t\t\t Act, shall be assessed for all abbreviated applications for a generic new\n\t\t\t animal drug and supplemental abbreviated applications for a generic new animal\n\t\t\t drug received on or after October 1, 2013, regardless of the date of enactment\n\t\t\t of this Act.", "@entity-type": "act", "#text": "part 5 of subchapter C of\n\t\t\t chapter VII of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5"}, "#text": "The amendments made by\n\t\t\t this Act shall take effect on October 1, 2013, or the date of enactment of this\n\t\t\t Act, whichever is later, except that fees under ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n      ", "#text": "Effective\n\t\t\t date"}, "#text": "\n      ", "@id": "H42E95AE49C054A7D9BBD0CE29843780F"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n\t\t\t", "#text": "Sunset\n\t\t\t dates"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " shall cease\n\t\t\t to be effective October 1, 2018.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section\n\t\t\t 741 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:741", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/379j-21", "#text": "21 U.S.C. 379j\u201321", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Authorization"}, "#text": "\n        ", "@id": "H6842533F0935497A902F71263C64858B"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " shall cease to be effective January 31, 2019.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 742 of the Federal Food, Drug, and Cosmetic\n\t\t\t Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:742", "@proposed": "true"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/379j-22", "#text": "21 U.S.C. 379j\u201322", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Reporting\n\t\t\t requirements"}, "#text": "\n        ", "@id": "H3172FE1DAFFC4DAEA630203A5C80B897"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Previous sunset\n\t\t\t provision"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is repealed.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 204 of the Animal Generic Drug User Fee Act of\n\t\t\t 2008", "@value": "Animal Generic Drug User Fee Act of 2008/s:204"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "@parsable-cite": "pl/110/316", "#text": "Public Law 110\u2013316", "@legal-doc": "public-law"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "#text": "\n          ", "@id": "HC33D2BA160DC4E80B4728BBA248E8AB0", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", by striking the\n\t\t\t item relating to ", "@entity-type": "act", "#text": "section 1", "@value": "Animal Generic Drug User Fee Act of 2008/s:1"}, {"#tail": ".", "@entity-type": "act", "#text": "section 204", "@value": "Animal Generic Drug User Fee Act of 2008/s:204"}], "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended in the table of contents in ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Animal Generic Drug User Fee Act of 2008", "@value": "Animal Generic Drug User Fee Act of 2008"}, {"#tail": ")", "@entity-type": "public-law", "#text": "Public\n\t\t\t Law 110\u2013316", "@value": "public-law/110/316"}], "@entity-type": "law-citation", "#text": "\n              "}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Conforming\n\t\t\t amendment"}, "#text": "\n          ", "@id": "H51E7D14A8E8C4EAA8AED6CDFB1860802", "@commented": "no"}], "#text": "\n        ", "@id": "HDDACE7C71787476689CDC13A243E984D", "@commented": "no"}], "#text": "\n      ", "@id": "HE455ED913E0C4371B47D7FC16C3DFFD2"}], "#text": "\n\t\t", "@id": "HC08FB21E27F04BE6A5D622641A9B645F"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-04-09"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 1408 IH: Animal Generic Drug User Fee Amendments of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}